Empfehlungen für die Auswahl von Inhalationssystemen zur Medikamentenverabreichung

Die inhalative Applikation von Medikamenten ist die bedeutsamste Form der Behandlung von obstruktiven Atemwegserkrankungen [30] [75] [99]. Gründe hierfür sind die hohe lokale Wirkstoffkonzentration bei geringer Gesamtdosis und das damit verbundene günstige Wirkungs-/Nebenwirkungsverhältnis (z. B. Glukokortikoide) sowie der rasche Wirkungseintritt (z. B. Beta-2-Adrenergika) [2] [73] [113] [114]. Neben Medikamenten zur topischen Therapie wird zunehmend die Inhalation verschiedener Substanzen zur systemischen Behandlung geprüft [17] [19] [59] [60] [65] [93]. Darüber hinaus werden neue Applikationssysteme entwickelt [93]. Die große Auswahl von Inhalationssystemen führt nicht selten zu einer Unsicherheit bei Ärzten und Patienten, obgleich sie die Möglichkeit bietet, für jeden individuellen Fall ein geeignetes System auszuwählen. Hierfür ist die Kenntnis einiger Grundsätze der Aerosolmedizin und technologischer Aspekte der Inhalationsbehandlung erforderlich.

Ziel jeder Inhalationstherapie muss es sein, dem Patienten ein System zur Verfügung zu stellen, das einfach zu handhaben ist, eine hohe Dosiskonstanz und eine optimale Deposition im gewünschten Bereich des Atemtraktes ermöglicht [8] [13] [95].

Literatur

• 1 Ad Hoc Committee on Health Literacy for the Council of Scientific Affairs, American Medical Association, Health Literacy . Report of the Council of Scientific Affairs.  JAMA. 1999;  281 552-557
• 2 Aerosol Consensus Statement . Chest. 1991;  100 1106-1109
• 3 Alvine G F, Rodgers P, Fitzsimmons K M, Ahrens R C. Disposable jet nebulisers. How reliable are they?.  Chest. 1992;  101 316-319
• 4 Armitage J M, Williams S J. Inhaler technique in the elderly.  Age and Ageing. 1988;  17 275-278
• 5 Barry P, O'Callaghan C. Multiple actuations of salbutamol MDI into a spacer device reduce the amount of drug recovered in the respirable range.  Eur Respir J. 1994;  7 1707-1709
• 6 Barry P, O'Callaghan C. Poor output of salbutamol from a spacer device - the effect of spacer static charge and multiple actuations.  Thorax. 1994;  49 402
• 7 van Beerendonk I, Mesters I, Mudde A N, Tan T D. Assessment of the inhalation technique in outpatients with asthma or chronic obstructive pulmonary disease using a metered-dose inhaler or dry powder device.  J Asthma. 1998;  35 273-279
• 8 Boe J, Dennis J H. European respiratory society nebulizer guidelines: technical aspects.  Eur Respir Rev. 2000;  10 (Rev. 72) 1-237
• 9 Borgström L, Asking L, Beckman O, Bondesson E, Källén A, Olsson B. Discrepancy between in vitro and in vivo dose variability for a pressurized metered dose inhaler and a dry powder inhaler.  J Aersosol Med. 1998;  11 (Suppl. 1) 59-64
• 10 Braunstein G L, Trinquet G, Harper A E. Compliance with nedocromil sodium and a nedocromil sodium/salbutamol combination.  Eur Respir J. 1996;  9 893-898
• 11 Brenner M. Use of steroids in pediatric asthma.  Pediatr Ann. 1989;  18 810 - 813, 816-818 (Review)
• 12 Brindley A, Sumby B S, Smith I J, Prime D. et al . Design, manufacture and dose consistancy of the serevent diskus inhaler.  Pharm Tech Eur. 1995;  1 14-22
• 13 British Thoracic Society, National Asthma Campaign, Royal College of Physicians of London et al . The British guidelines on asthma management: 1995 review and position statement.  Thorax. 1997;  22 (Suppl. 1) S11
• 14 Brown P H, Ning A CWS, Greening A P, McLean A, Crompton G K. Peak inspiratory flow through Turbohaler® in acute asthma.  Eur Respir J. 1995;  8 1940-1941
• 15 Brown P H, Blundell G, Greening A P, Crompton G K. Do large spacer devices reduce the systemic effects of high dose inhaled corticosteroids?.  Thorax. 1990;  45 736-739
• 16 Bundesinstitut für Arzneimittel und Medizinprodukte . Bekanntmachung über die Zulassung und Registrierung sowie die Verlängerung der Zulassung von Arzneimitteln - Ausnahmen vom Verbot bestimmter die Ozonschicht abbauender Halogenkohlenwasserstoffe nach der FCKW-Halon-Verbots-Verordnung.  Bundesanzeiger. 2000;  4 141
• 17 Byron P R. Pulmonary targeting with aerosols.  Pharm Technol. 1987;  5 42-54
• 18 Byron P R, Peart J, Staniforth J N. Aerosol electrostatics. I: Properties of fine powders before and after aerosolization by dry powder inhalers.  Pharm Res. 1997;  14 698-705
• 19 Byron P R, Patton J S. Drug delivery via the respiratory tract.  J Aerosol Med. 1994;  7 49-75
• 20 Chinn S, Arossa W A, Jarvis D L, Luczynska C M, Burney P G. Variation in nebulizer aerosol output and weight output from the Mefar disometer: implications for multicentre studies.  Eur Respir J. 1997;  10 452-456
• 21 Clark A R, Hollingworth A M. The relationship between powder inhaler resistance and peak inspiratory conditions in healthy human volunteers - implications for in vitro testing.  J Aerosol Sci. 1993;  6 99-110
• 22 Cochrane G M, Horne R, Chanez P. Compliance in asthma.  Respir Med. 1999;  93 763-769
• 23 Cochrane G M, Bala M V, Downs K E, Mauskopf J, Ben-Joseph R H. Inhaled corticosteroids for asthma therapy. Patients compliance, devices, and inhalation technique.  Chest. 2000;  117 542-550
• 24 Crompton G K. Dry powder inhalers: advantages and limitations.  J Aerosol Med. 1991;  3 151-156
• 25 Crompton G. Problems patients have using pressurized aerosol inhalers.  Eur J Respir Dis. 1982;  63 (Suppl. 119) 101-104
• 26 Dalby R N, Tiano S L, Hickey A J. Medical devices for the delivery of therapeutic aerosols to the lung. In: Hichey AJ (Hrsg). Inhalation Aerosols: Physical and Biological Basis for Therapy New York: Marcel Dekker 1996: 441-474
• 27 Davadason S G, Everard M L, Linto J M, Le Souef P N. Comparison of drug delivery from conventional versus Venturi 1/2 nebulizers.  Eur Respir J. 1997;  10 2479-2483
• 28 Dekhuijsen P NR. Inhalatiemedicatie bij volwassenen met obstructieve longaandoeningen: poeder of aërosol?.  Ned Tijdschr Gneeskd. 1998;  141 1369-1374
• 29 Dennis J H. Drug nebulizer design and performance: Breath enhanced jet vs. constant output jet vs. ultrasonic.  J Aerosol Med. 1995;  8 277-280
• 30 Dennis J H, Hendrick D J. Design characteristics for drug nebulizers.  J Med Eng Technol. 1992;  16 63-68
• 31 Deutsche Atemwegsliga . Inhalationstherapie bei obstruktiven Atemwegserkrankungen.  Pneumologie. 1994;  48 338-341
• 32 Deutsche Atemwegsliga . Positionspapier zu Treibgasen in Dosieraerosolen.  Med Klinik. 1995;  90 617 (Nr. 11)
• 33 Dewsbury N J, Kenyon C J, Newman S P. The effect of handling techniques on electrostatic charge on spacer devices: a correlation with in vivo particle size analysis.  Int J Parm. 1996;  137 216-264
• 34 Egermann H. Mischen von Feststoffen. In: Hagers Handbuch der pharmazeutischen Praxis, Band 2: Methoden Berlin: Springer Verlag 1991
• 35 Everard M L, Dolovich M. In vivo measurements of lung dose. In: Risgaard M, O'Callaghan C, Smaldone G (Hrsg). Drug delivery in the lung: clinical aspects. Lung biology in health and disease New York: Marcel Dekker 2000: (in press)
• 36 Farrer M, Francis A J, Pearce S J. Monitoring serum cortisol concentration after 2 mg inhaled beclomethasone dipropionate in normal subjects: effect of a 750 ml spacing device.  Thorax. 1990;  45 740-742
• 37 Fergusson R J, Lenney J, McHardy G JR, Crompton G K. The use of the Autohaler® device by patients with severe airflow obstruction.  Eur Resp J. 1991;  4 172-174
• 38 Ferin J, Mercer T T, Leach L J. The effect of aerosol charge on the deposition and clearance of TiO₂ particles in rats.  Environ Res. 1983;  31 148-151
• 39 Ferron G A, Oberdörster G, Henneberg R. Estimation of the deposition of aerosolized drugs in the human respiratory tract due to hygroscopic growth.  J Aerosol Med. 1989;  2 271-284
• 40 Friegang B. New method of beclometasone aerosol administration to children under 4 years of age.  Can Med Assoc J. 1977;  117 1308-1309
• 41 Frieß S, Kutz G. Pulverinhalatoren: vom feindispersen System zum fertigen Arzneimittel.  Dtsch Apoth Ztg. 1993;  133 1242-1245
• 42 Gottschalk B, Leupold W, Woller P. Fundamental investigations for the deposition of aerosols from radioactive solutions in the upper and lower airways.  Z Erkr Atmungsorgane. 1979;  153 355-366
• 43 Hallworth G W. The formulation and evaluation of pressurized metered-dose inhalers. In: Ganderton D, Jones T (Hrsg). Drug Delivery to the Respiratory Tract Weinheim: VCH 1987: 87-118
• 44 Hansen N CG, Eyald T, Ibsen T B. Terbutaline inhalations by the Turbohaler® as replacement for domiciliary nebulizer therapy in severe chronic obstructive pulmonary disease.  Respir Med. 1994;  88 267-271
• 45 Heyder J. Deponierung von Aerosolteilchen im Atemtrakt des Menschen. In: Scheuch G. Aerosole in der Inhalationstherapie München: Dustri 1997: 1-10
• 46 Heyder J, Gebhart J, Rudolf G, Schiller C F. et al . Deposition of particles in the human respiratory tract in size range 0,005 - 15 µm.  J Aerosol Sci. 1986;  17 811-825
• 47 Hickey A J, Concessio N M, van Oort M M, Platz R M. Factors influencing the dispersion of dry powders as aerosols.  Pharm Tech. 1994;  8 58-82
• 48 Hickey A J, Evans R M. Aerosol generation from propellant-driven MDIs. In: Hichey AJ (Hrsg.). Inhalation Aerosols: Physicals and Biological Basis for Therapy New York: Marcel Dekker 1996: 417-440
• 49 Hindle M, Byron P R. Dose emissions from marketed dry powder inhalers.  Int J Pharmaceut. 1995;  116 169-177
• 50 Holzner P. FCKW-freie Aerosole und Dispergiersysteme. In: Müller RH, Hildebrand GE (Hrsg.). Pharmazeutische Technologie - Moderne Arzneiformen Stuttgart: Wissenschaftliche Verlagsgesellschaft mbH 1996: 31-36
• 51 Holzner P. Pharmazeutische Aerosole: Methoden zur Erzeugung, Charakterisierung und Bewertung (Dissertation). Kiel: Christian-Albrechts-Universität Kiel 1995
• 52 Holzner P, Müller B W. An in vitro evaluation of various spacer devices for metered dose inhalers using the twin impinger.  Int J Pharm. 1994;  106 69-75
• 53 Ip A Y, Arakawa T, Silvers H, Ransone C M, Niven R W. Stability of recombinant consensus interferon to air-jet and ultrasonic nebulisation.  J Pharm Sci. 1995;  84 1210-1214
• 54 Janssens H M, Devadason S G, Hop W CJ. et al . Varibility of aerosol delivery via spacer devices in young children in daily life.  Eur Respir J. 1999;  13 787-791
• 55 June D. Achieving the change: challenges and successes in the formulation of CFC-free MDI's.  Eur Respir Rev. 1997;  7 32-34
• 56 Kim C S, Trujillo D, Sackner M A. Size aspects of metered-dose inhaler aerosols.  Am Rev Respir Dis. 1985;  132 137-142
• 57 Knoch M, Sommer E. Jet nebulizer design and function.  Eur Respir Rev. 2000;  10 (Rev. 72) 183-186
• 58 Knoch M, Wunderlich E, Geldner S. A nebulizer system for highly reproducible aerosol delivery.  J Aerosol Med. 1994;  7 229-237
• 59 Köhler D. Aerosols for systemic treatment.  Lung. 1990;  168 (Suppl.) 677-684 (Review)
• 60 Köhler D. Systemic therapy with aerosols. In: Moran F, Dolovich MB, Newhouse MT, Newman SP (Hrsg.). Aerosols in Medicine Amsterdam: Elsevier Sci 1993: 303-319
• 61 Köhler D. Wirksamkeit und Akzeptanz von Pulverinhalatoren.  Dtsch Med Wochenschr. 1995;  120 1401-1404
• 62 Köhler D, Grossmann J, Schümichen C, Vastag E, Matthys H. Comparing efficacy of various adrenergic MDIs with the recommended expander systems.  Bull Europ Physiopath Resp. 1986;  22 662s
• 63 Köhler D, Simonides R, Rothfuss J, Vastag E, Daikeler G, Matthys H. Aerosolverteilungsmuster von 16 handelsüblichen Aerosolgeräten.  Prax Klin Pneumol. 1983;  37 (Suppl. 1) 922-924
• 64 Köhler D, Fleischer W, Matthys H. Depositionsmuster von Dosieraerosolen im menschlichen Organismus.  Atemw Lungenkrkh. 1985;  11 340-341
• 65 Köhler D, Fleischer W. Theorie und Praxis der Inhalationstherapie. München: Arcis 2000
• 66 Leach C L. Approaches and challenges to use freon propellant replacements.  Aerosol Sci Technol. 1995;  22 329-334
• 67 Leach C L. Enhanced drug delivery through reformulating MDIs with HFA propellant-drug deposition and its effect on preclinical and clinical programs. In: Dalby RN, Byron PR, Farr SJ (Hrsg.). Respiratory Drug Delivery V Buffalo Grove: Interpharm Press 1996: 133-144
• 68 Marshik P L. et al . A novel breath actuated device (Autohaler®) consistently actuates during the early phase of inspiration.  J Aerosol Med. 1995;  8 187-195
• 69 Martonen T B, Katz I. Deposition mechanics of pharmaceutical particles in human airways. In: Hichey AJ (Hrsg). Inhalation Aerosols: Physical and Biological Basis for Therapy New York: Marcel Dekker 1996: 3-28
• 70 Martonen T B, Katz I. Deposition patterns of aerosolized drugs within human lungs: effects of ventilatory parameters.  Pharm Res. 1993;  10 871-878
• 71 Melandri C, Prodi V, Tarroni G, Formignani M, De Zaiacomo T, Bompane G F, Maestri G. On the deposition of unipolarly charged particles in the human respiratory tract.  Inhaled Part Pt. 1975;  1 193-201
• 72 Merkus P J, van Essen-Zandfliet E E, Parlevliet E, Borsboom G, Sterk P J, Kerrebijn K F, Quanjer P H. Changes of nebulizer output over the years.  Eur Respir J. 1992;  5 448-491
• 73 Morrow-Brown H, Storey G, George W HS. Beclomethasone dipropionate: a new steroid aerosol for the treatment of allergic asthma.  BMJ. 1972;  2 585-590
• 74 Nana A, Youngchaiyud P, Maranetra N, Boe J, Löfdahl C.-G, Selroos O, Ståhl E. β₂-agonists administered by a dry powder inhaler can be used in acute asthma.  Respir Med. 1998;  92 167-172
• 75 Newhouse M T. Aerosolerzeugung und Verteilungssysteme zur pulmonalen Medikamentenapplikation: Theorie und Praxis.  Innere Medizin. 1993;  48 363-368
• 76 Newman S A, Morén F, Pavia D, Little F. et al . Deposition of pressurized suspension aerosols inhaled through extension devices.  Am Rev Respir Dis. 1981;  124 17-20
• 77 Newman S P, Hollingworth A, Clark A R. Effect of different modes of inhalation on drug delivery from a dry powder inhaler.  Int J Pharm. 1994;  102 127-132
• 78 Newman S P, Millar A B, Lennard-Jones T R, Morén F. et al . Improvement of pressurized aerosol deposition with the nebuhaler spacer device.  Thorax. 1984;  39 935-941
• 79 Newman S P, Weisz A WB, Talaee N, Clarke S W. Improvement of drug delivery with a breath actuated pressurized aerosol for patients with poor inhaler technique.  Thorax. 1991;  46 712-716
• 80 Newman S P, Morén F, Trofast E, Talaee N. et al . Terbutaline sulphate turbohaler: effect of inhaled flow rate on drug deposition and efficacy.  Int J Pharm. 1991;  74 209-213
• 81 Newman S P, Morén F, Trofast E, Talaee N, Clarke S W. Deposition and clinical efficacy of terbutaline sulphate from Turbohaler, a new multi-dose powder inhaler.  Eur Respir J. 1989;  2 247-252
• 82 Newman S P, Newhouse M T. Effect of add-on devices for aerosol drug delivery: deposition studies and clinical aspects.  J Aerosol Med. 1996;  9 55-70
• 83 Nides M A, Tashkin D P, Simmons M S. et al . Improving inhaler adherence in a clinical trial through the use of a nebulizer chronolog.  Chest. 1993;  104 1332-1337
• 84 Nikander K. Drug delivery systems.  J Aerosol Med. 1994;  7 S19-24
• 85 Nikander K, Turpeinen M, Wollmer P. The conventional ultrasonic nebuliser proved inefficient in nebulising a suspension.  J Aerosol Med. 1999;  12 (Suppl. 2) 47-53
• 86 Niven R W, Ip A Y, Mittelman S, Prestrelski S J, Arakawa T. Some factors associated with the ultrasonic nebulization of proteins.  Pharm Res. 1995;  12 53-59
• 87 O'Callaghan C, Cant M, Robertson C. Delivery of beclomethasone dipropionate from a spacer device: what dose is available for inhalation?.  Thorax. 1994;  49 961-964
• 88 O'Callaghan C, Lynch J, Cant M, Robertson C. Improvement in sodium cromoglycate delivery from a spacer device by use of an antistatic lining, immediate inhalation, and avoiding multiple actuation of drug.  Thorax. 1993;  48 603-606
• 89 O'Driscoll R. Review of methodology and development of UK nebulizer guidelines (1997) prepared by the British Thoracic Society.  Eur Respir Rev. 2000;  10 (Rev. 72) 203-205
• 90 Olsson B, Asking L. Critical aspects of the function of inspiratory flow driven inhalers.  J Aerosol Med. 1994;  7 (Suppl. 1) 43-47
• 91 van der Palen J. Multiple inhalers confuse asthma patients.  Eur Respir J. 1999;  14 1034-1037
• 92 Partridge M R, Woodcock A, Sheffler A L. et al . Chlorofluorocarbon-free inhalers: are we ready for the change?.  Eur Respir J. 1998;  11 1006-1008
• 93 Patton J S, Bukar J, Nagarajan S. Inhaled insulin.  Adv Drug Deliv Rev. 1999;  35 235-247
• 94 Pedersen S. How to use a rotahaler.  Arch Dis Child. 1986;  61 11-14
• 95 Petro W, Gebert P, Lauber B. Ursachen fehlerhafter Anwendung von Dosieraerosolen.  Pneumologie. 1994;  48 191-196
• 96 Pierart F, Wildhaber J H, Vrancken I, Devadason S G, Le Souef P N. Washing plastic spacers in household detergent reduces electrostatic charge and greatly improves delivery.  Eur Respir J. 1999;  13 673-678
• 97 Ross D L, Schultz R K. Effect on inhalation flow rate on the dosing characteristics of dry powder inhaler (DPI) and metered dose inhaler (MDI) products.  J Aerosol Med. 1996;  9 215-226
• 98 Sackner M A, Chong C S. Auxiliary MDI aerosol delivery systems.  Chest. 1985;  88 161-169
• 99 Sakula A. A history of asthma.  J R Coll Physicians Lond. 1988;  22 36-44
• 100 Saunders K B. Misuse of inhaled bronchodilator agents.  BMJ. 1965;  1 1037-1038
• 101 Self T H, Rumbak M J, Kelso T M. Correct use of metered-dose inhalers and spacer devices.  Postgrad Med. 1992;  92 95-106
• 102 Shim C. Spacer disuse.  Am J Respir Crit Care Med. 2000;  161 A320
• 103 Smith E C, Denyer J, Kendrick A H. Comparison of twenty three nebulizer/compressor combinations for domiciliary use.  Eur Respir J. 1995;  8 1214-1221
• 104 Smith K J, Chan H.-K, Brown K F. Influence of flow rate on aerosol particle size distributions from pressurized and breath-actuated inhalers.  J Aerosol Med. 1998;  11 231-245
• 105 Stahlhofen W, Gebhardt J, Heyder J. Experimental determination of the regional deposition of aerosol particles in the human respiratory tract.  Am Ind Hyg Assoc J. 1980;  41 385-397
• 106 Svartengren K, Lindestad P.-A, Svartengren M, Philipson K, Bylin G, Cammer P. Added external resistance reduces oropharyngeal deposition and increases lung deposition of aerosol particles in asthmatics.  Am J Respir Crit Care Med. 1995;  152 32-37
• 107 Tang I N, Munkelwitz H R, Davis J G. Aerosol growth studies. III.  J Aerosol Sci. 1977;  8 321-330
• 108 The COPD guidelines group of the standards of care committee of the BTS . BTS guidelines for the management of chronic obstructive pulmonary disease.  Thorax. 1997;  52 (Suppl. 5) 1-28
• 109 Thompson J, Irvine T H, Grathwohl K, Roth B. Misuse of metered-dose inhalers in hospitalized patients.  Chest. 1994;  105 715-717
• 110 Thorsson L, Edsbacker S. Lung deposition from a pressurised metered dose inhaler attached to a spacer.  Eur Respir J. 1998;  12 1340-1345
• 111 Tiano S L, Dalby R N. Comparison of a respiratory suspension aerosolized by an airjet and an ultrasonic nebuliser.  Pharm Dev Technol. 1996;  1 261-268
• 112 Vidgen M T, Patronen T P, Kärkkäinen A, Karjalainen P. Effect of extension devices on the drug deposition from inhalation aerosols.  Int J Parm. 1987;  39 107-112
• 113 Visser J. Van der Waals and other cohesive forces affecting powder fluidization.  Powder Technol. 1989;  58 1-10
• 114 Webb J, Rees J, Clark T J. A comparison of the effects of different methods of administration of beta 2 sympathomimetics in patients with asthma.  Br J Dis Chest. 1982;  76 351-357
• 115 Weber A, Morlin G, Cohen M, Williams-Warren J, Ramsey B, Smith A. Effect of nebuliser type and antibiotic concentration on device performances.  Pediatr Pulmonol. 1997;  23 249-260
• 116 Wettengel R, Berdel D, Hoffmann D, Krause J, Kroegel C, Kroidl R F, Leupold W, Lindemann H, Magnussen H, Meister R, Moor H, Nolte D, Rabe K F, Reinhardt D, Sauer R, Schultze-Werninghaus G, Ukena D, Worth H. Asthmatherapie bei Kindern und Erwachsenen. Empfehlungen der Deutschen Atemwegsliga in der Deutschen Gesellschaft für Pneumologie.  Med Klin. 1998;  93 639-650
• 117 Wetterlin K. Turbohaler: a new powder inhaler for administration of drugs to the airways.  Pharm Res. 1988;  5 506-508
• 118 Wigley F W, Londono J H, Wood S H, Shipp J C, Waldman R H. Insulin across respiratory mucosae by aerosol delivery.  Diabetes. 1971;  20 552-556
• 119 Wildhaber J H, Devadason S G, Hayden M J, James R, Dufty A P, Fox R A, Summers Q A, Le Souef P N. Electrostatic charge on a plastic spacer device influences the delivery of salbutamol.  Eur Respir J. 1996;  9 1943-1946
• 120 Winsel K, Bergmann K C, Lachmann B. Untersuchungen über die Ultraschallverneblung von oberflächenaktiven Stoffen aus Lungengewebe und Lecithin-Dispersionen im Hinblick auf die künstliche Befilmung von Lungen.  Z Erkr Atmungsorgane. 1974;  140 151-158
• 121 Zanen P, van Spiegel P I, van der Kolk H, Tushuisen E. et al . The effect of the inhalation flow on the performance of a dry powder inhalation system.  Int J Pharm. 1992;  81 199-203